Loading...
XNASEVGN
Market cap7mUSD
Dec 24, Last price  
1.46USD
1D
8.11%
1Q
-41.85%
Jan 2017
-71.38%
IPO
-87.13%
Name

Evogene Ltd

Chart & Performance

D1W1MN
XNAS:EVGN chart
P/E
—
P/S
1.39
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-29.24%
Rev. gr., 5y
26.41%
Revenues
6m
+236.72%
14,901,00017,072,00017,581,00014,511,00011,129,0006,540,0003,381,0001,747,000753,0001,040,000930,0001,675,0005,640,000
Net income
-24m
L-10.36%
645,000-2,522,000-8,878,000-14,530,000-17,213,000-19,592,000-20,838,000-20,758,000-18,112,000-23,374,000-27,793,000-26,638,000-23,879,000
CFO
-22m
L-8.87%
2,133,000-1,888,000-5,270,000-8,895,000-12,407,000-11,693,000-15,929,000-15,161,000-17,364,000-19,514,000-24,839,000-23,678,000-21,577,000
Earnings
Mar 05, 2025

Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
URL
https://evogene.com/
IPO date
Jun 11, 2007
Employees
137
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
5,640
236.72%
1,675
80.11%
930
-10.58%
Cost of revenue
32,031
32,116
32,536
Unusual Expense (Income)
NOPBT
(26,391)
(30,441)
(31,606)
NOPBT Margin
Operating Taxes
(33)
90
13
Tax Rate
NOPAT
(26,358)
(30,531)
(31,619)
Net income
(23,879)
-10.36%
(26,638)
-4.16%
(27,793)
18.91%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,449
21
29,582
BB yield
-220.16%
-0.73%
-446.11%
Debt
Debt current
853
884
974
Long-term debt
11,791
12,862
4,364
Deferred revenue
4,426
4,665
4,307
Other long-term liabilities
393
18,432
Net debt
(18,419)
(21,609)
(48,528)
Cash flow
Cash from operating activities
(21,577)
(23,678)
(24,839)
CAPEX
(785)
(1,171)
(724)
Cash from investing activities
(4,538)
13,274
(20,443)
Cash from financing activities
18,152
9,343
30,276
FCF
(25,726)
(30,416)
(31,857)
Balance
Cash
31,063
35,355
53,866
Long term investments
Excess cash
30,781
35,271
53,820
Stockholders' equity
(240,668)
34,790
63,042
Invested Capital
285,678
35,027
16,576
ROIC
ROCE
EV
Common stock shares outstanding
4,569
4,121
4,043
Price
0.84
20.00%
0.70
-57.32%
1.64
-65.11%
Market cap
3,838
33.03%
2,885
-56.50%
6,631
-49.90%
EV
2,051
(11,864)
(32,508)
EBITDA
(23,779)
(27,861)
(29,372)
EV/EBITDA
0.43
1.11
Interest
171
3,329
1,414
Interest/NOPBT